Cysteinyl leukotriene receptor CysLT1 as a novel therapeutic target for allergic rhinitis treatment

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 4, 2008, Pages 415-423

  Shirasaki, Hideaki ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Allergic rhinitis; CysLT1 receptor; Cysteinyl leukotriene

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; ANTIHISTAMINIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; CYSTEINYL LEUKOTRIENE 1 RECEPTOR; CYSTEINYL LEUKOTRIENE RECEPTOR BLOCKING AGENT; DESLORATADINE; FLUTICASONE; G PROTEIN COUPLED RECEPTOR; HISTAMINE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MONTELUKAST; PEPTIDOLEUKOTRIENE; PLACEBO; PRANLUKAST; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON; LEUKOTRIENE D4 RECEPTOR; MEMBRANE PROTEIN;

ALLERGIC RHINITIS; ASTHMA; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; REVIEW; TISSUE DISTRIBUTION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; EOSINOPHIL; HAY FEVER; MACROPHAGE; MAST CELL; METABOLISM; NOSE MUCOSA; PERENNIAL RHINITIS;

DRUG DELIVERY SYSTEMS; EOSINOPHILS; HUMANS; MACROPHAGES; MAST CELLS; MEMBRANE PROTEINS; NASAL MUCOSA; RECEPTORS, LEUKOTRIENE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 42149155647     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.4.415     Document Type: Review

References (83)

1. Capra V, Thompson MD, Sala A, et al. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 2007;27:469-527
2. Numata T, Konno A, Yamakoshi T, et al. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 1999;108:467-73
3. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo- controlled clinical trial. J Allergy Clin Immunol 2000;105:917-22
4. Philip G, Malmstrom K, Hampel FC Jr, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8
5. Nayak-AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-600
6. van Adelsberg J, Philip G, LaForce CF. et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-22
7. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-9
8. Jiang RS. Efficacy of a leukotriene receptor antagonist in the treatment of perennial allergic rhinitis. J Otolaryngol 2006;35:117-21
9. Piatti G, Ceriotti L, Cavallaro G, et al. Effects of zafirlukast on bronchial asthma and allergic thinitis. Pharmacol Res 2003;47:541-7
10. Phipatanakul W, Eggleston PA, Conover-Walker MK, et al. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory response to cat challenge. J Allergy Clin Immunol 2000;105:704-10
11. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999;399:789-93
12. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000;275:30531-6
13. Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy 2002;32:1007-12
14. Funk CD. Proataglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-5
15. Chrismas P, Weber BM, McKee M, et al. Membrane localization and topology of leukotriene C4 synthase. J Biol Chem 2002;277:28902-8
16. Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999;56:657-63
17. Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT2 receptor. Biochem Biophys Res Commun 2000;274:316-22
18. Mellor EA, Frank N, Soler D, et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R. Proc Natl Acad Sci USA 2003;100:11589-93
19. Rovati GE, Capra V. Cysteinyl-leukotriene receptors and cellular signals. Sci World J 2007;7:1375-92
20. Figueroa DJ, Breyer R, Defoe S, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001;163:226-33
21. Mita H, Hasegawa M, Saito H, Akiyama K. Levels of cysteinyl leukotriene receptor mRNA in human peripheral leukocytes: significantly higher expression of cysteinyl leukotriene 2 mRNA in eosinophils. Clin Exp Allergy 2001;31:1714-23
22. Jones TR, Labelle M, Belley M, et al. Pharmacology of montelukast sodium (singulair), a potent and selective leukotriene D4 receptor antagonists. Can J Physiol Pharmacol 1995;73:191-201
23. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Am Rev Respir Dis 1990;141(4 Pt 1):978-87
24. Obata T, Nanbu F, Kitagawa T, et al. ONO-1078: an antagonist of leukotrienes. Adv Prostaglandin Thromboxane Leukot Res 1987;17A:540-3
25. Capra V, Ambrosio M, Riccioni G, et al. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006;13:3213-26
26. 1 receptor antagonists with respect to LTC4 and LTD4 in human lung parenchyma. Biochem Pharmacol 2002;63:1537-46
27. Labat C, Ortiz JL, Norel X, et al. A second cysteinyl leukotriene receptor human lung. J Pharmacol Exp Ther 1992;263:800-5
28. Walden SM, Proud D, Bascom R, et al. Experimentally increased nasal allergic responses. J Allergy Clin Immunol 1988;81(5 Pt 2):940-9
29. Miadonna A, Tedeschi A, Leggieri E, et al. Behavior and clinical relevance of histamine and leukotriene C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987;136:357-62
30. Wang D, Clement P, Smitz J, et al. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995;106:278-85
31. Shirasaki H, Asakura K, Kojima T, et al. The roles of histamine, leukotriene C4 and bradykinin on nasal vascular permeability in experimental nasal allergy of guinea pigs. Rhinology 1992;30:41-8
32. Figueroa DJ, Borish L, Baramki D, et al. Expression of cysteinyl leukotriene synthetic and signaling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 2003;33:1380-8
33. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-97
34. Okuda M, Watase T, Mezawa A, et al. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-40
35. Narita S, Asakura K, Shirasaki H, Kataura A. Effects of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast), on total airway resistance after antigen challenge in sensitized guinea pigs. Inflamm Res 1997;46:143-6
36. Shirasaki H, Asakura K, Narita S, Kataura A. The effect of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast) on agonist- and antigen-induced nasal microvascular leakage in guinea pigs. Rhinology 1998;36:62-5
37. Munoz NM, Douglas I, Mayer D, et al. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med 1997;155:1398-403
38. Reiss TF, Chervinski P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-20
39. Lee E, Robertson T, Jacqueline S, Kilfeather S. Lcukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000;161:1881-6
40. Shirasaki H, Kanaizumi E, Seki N, et al. Distribution of specific binding sites for cysteinyl leukotriene 1 receptor antagonist in human nasal mucosa. Acta Otolaryngol 2006;126:948-51
41. Hisamatsu K, Nakajima M. Pranlukast protects Leukotriene C4- and D4-induced epithelial cell impairment of the nasal mucosa in vitro. Life Sci 2000;67:2767-73
42. Saano JS, Koskela T, Toskala E, et al. Effect of leukotriene D4 on ciliary activity in human, guinea-pig and rat respiratory mucosa. Pulm Pharmacol 1996;9:231-8
43. Bisgaard H, Pedersen M. SRS-A leukotriene decrease the activity of human respiratory cilia. Clin Allergy 1987;17:95-103
44. Schuil P, Gelder J, Berg M, et al. Histamine and leukotriene C4 effects on in vitro ciliary beat frequency of human upper respiratory cilia. Eur Arch Otorhinolaryngol 1994;251:325-8
45. Labat C, Bara J, Gascard JP, et al. M1/MUC5AC mucin released by human airways in vitro. Eur Respir J 1999;14:390-5
46. Shirasaki H, Seki N, Fujita M, et al. Agonist-and T(H)2 cytokine-induced up-regulation of cysteinyl leukotriene receptor messenger RNA in human monocytes. Ann Allergy Asthma Immunol 2007;99:340-7
47. Ghaffar O, Laberge S, Jacobson MR, et al. IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy. Am J Respir Cell Mol Biol 1997;17:17-24
48. Kroegel C, Julius P, Matthys H, et al. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 1996;9:899-904
49. Sausa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493-9
50. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323:1745-8
51. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: A systematic review and meta-analysis. Am J Med 2004;116:338-44
52. Wilson AM, Dempsey C, Sims S, et al. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 2000;38:833-8
53. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:949-55
54. Ciebiana M, Gorska-Ciebiada M, DuBuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:664-71
55. Wilson AM, Orr LC, Sims EJ, Lipworrth BJ. Effects of monotherapy with intra-nasal corticosteroids or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001;31:61-8
56. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:344-9
57. Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine fluticason plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004;34:259-67
58. Saengpanich S, deTineo M, Naclerio RM, Baroody FM. Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Arch Otolaryngol Head Neck Surg 2003;129:557-62
59. Kanniess F, Richter K, Janicki S, et al. Dose reduction of inhaled corticosteroids under concominant medication with montelukast in patients with asthma. Eur Respir J 2002;20:1080-7
60. Perng DW, Huang HY, Lee YC, Perng RP. Leukotriene modifier vs inhaled corticosteroids in mild-to-moderate asthma. Chest 2004;125:1693-9
61. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-6
62. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001;31:616-24
63. Berger W, De Chandt MTM, Cairns CB. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007;61:663-76
64. Levy BD, De Sanctis GT, Devchand PR, et al. Multi-prolonged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat Med 2002;8:1018-23
65. Beller TC, Maekawa A, Friend DS, et al. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004;279:46129-34
66. Hui Y, Cheng Y, Smalera I, et al. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 2004;110:3360-6
67. Maekawa A, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of the cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 2002;277:20820-4
68. Park JS, Chang HS, Park CS, et al. Association analysis of cysteinyl-leukotriene receptor2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics 2005;15:483-92
69. Fukai H, Ogasawara Y, Migita O, et al. Association between a polymorphism in cysteinyl leukoriene receptor 2 on chromosome 13q14 and atopic asthma. Pharmacogenetics 2004;14:683-90
70. Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A(-444) C polymorphism and clinical response to a CYS-LT1 antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002;12:565-70
71. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-7
72. Drasen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206
73. Eskandari HG, Unal M, Ozturk OG, et al. Leukotriene C4 synthase A-444C gene polymorphism in patients with allergic rhinitis. Otolaryngol Head Neck Surg 2006;134:997-1000
74. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC4 synthase allele modified cysteinyl leukotriene synthesis in eosinophils and predics clinical response to zafirlukast. Thorax 2000;55:28-31
75. Kim SH, Ye YM, Hur GY, et al. CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. Phamacogenomics 2007;8:1143-50
76. Zang J, Migita O, Koga M, et al. Determination of structure and transcriptional regulation of CYSLTR1 and an association study with asthma and rhinitis. Pediatr Allergy Immunol 2006;17:242-9
77. Thompson MD, Capra V, Takasaki J, et al. A functional G300S variant of the cysteinyl leukotriene 1 receptor is associated with atopy in a Ttristan da Cunha isolate. Pharmacogenet Genomics 2007;17:539-49
78. Grossman J. One airway, one disease. Chest 1997;111:11S-16S
79. Dahlen SE. Cysteinyl leukotrienes as common mediators of asthma and allergic rhinitis. Clin Exp Allergy Rev 2003;3:69-73
80. Philip GP, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal rhinitis. Curr Med Res Opin 2004;20:1549-58
81. Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from COMPACT trial. Allergy 2006;61:737-42
82. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006;100:1952-9
83. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on Asthma. J Allergy Clin Immunol 2001;108 Suppl 5:S147-334